The diagnosis and management of malignant phaeochromocytoma and paraganglioma
- PMID: 17914089
- DOI: 10.1677/ERC-07-0074
The diagnosis and management of malignant phaeochromocytoma and paraganglioma
Abstract
Malignant phaeochromocytomas are rare tumours accounting for ~10% of all phaeochromocytomas; the prevalence of malignancy among paragangliomas is higher, especially those associated with succinate dehydrogenase subunit B gene mutations. Although a subset of these tumours has metastatic disease at initial presentation, a significant number develops metastases during follow-up after excision of an apparently benign tumour. Clinical, biochemical and histological features cannot reliably distinguish malignant from benign tumours. Although a number of recently introduced molecular markers have been explored, their clinical significance remains to be elucidated from further studies. Several imaging modalities have been utilised for the diagnosis and staging of these tumours. Functional imaging using radiolabelled metaiodobenzylguanidine (MIBG) and more recently, (18)F-fluorodopamine and (18)F-fluorodopa positron emission tomography offer substantial sensitivity and specificity to correctly detect metastatic phaeochromocytoma and paraganglioma and helps identify patients suitable for treatment with radiopharmaceuticals. The 5-year mortality rate of patients with malignant phaeochromocytomas and paragangliomas greater than 50% indicates that there is considerable room for the improvement of currently available therapies. The main therapeutic target is tumour reduction and control of symptoms of excessive catecholamine secretion. Currently, the best adjunctive therapy to surgery is treatment with radiopharmaceuticals using (131)I-MIBG; however, this is very rarely curative. Chemotherapy has been used for metastatic disease with only a partial and mainly palliative effect. The role of other forms of radionuclide treatment either alone or in combination with chemotherapy is currently evolving. Ongoing microarray studies may provide novel intracellular pathways of importance for proliferation/cell cycle control, and lead to the development of novel pharmacological agents.
Similar articles
-
Malignant pheochromocytomas and paragangliomas - the importance of a multidisciplinary approach.Cancer Treat Rev. 2011 Apr;37(2):111-9. doi: 10.1016/j.ctrv.2010.07.002. Epub 2010 Aug 2. Cancer Treat Rev. 2011. PMID: 20675056 Review.
-
Phaeochromocytomas and functional paragangliomas: clinical management.Best Pract Res Clin Endocrinol Metab. 2010 Dec;24(6):933-41. doi: 10.1016/j.beem.2010.10.002. Best Pract Res Clin Endocrinol Metab. 2010. PMID: 21115162
-
Malignant pheochromocytoma: state of the field with future projections.Ann N Y Acad Sci. 2006 Aug;1073:449-64. doi: 10.1196/annals.1353.049. Ann N Y Acad Sci. 2006. PMID: 17102114
-
Metastatic pheochromocytoma and paraganglioma.Eur J Clin Invest. 2015 Sep;45(9):986-97. doi: 10.1111/eci.12495. Eur J Clin Invest. 2015. PMID: 26183460 Review.
-
Diagnosis, localization and treatment of pheochromocytoma in MEN 2 syndrome.Endocr Regul. 2009 Apr;43(2):89-93. Endocr Regul. 2009. PMID: 19856714 Review.
Cited by
-
Development and validation of a simple, fast and sensitive liquid chromatography-tandem mass spectrometry method to establish reference intervals for 24-h urinary free normetanephrine, metanephrine and methoxytyramine.Pract Lab Med. 2024 Jan 23;39:e00358. doi: 10.1016/j.plabm.2024.e00358. eCollection 2024 Mar. Pract Lab Med. 2024. PMID: 38318432 Free PMC article.
-
Mesenteric Paraganglioma: A Case Report and Literature Review.Cureus. 2023 Sep 21;15(9):e45685. doi: 10.7759/cureus.45685. eCollection 2023 Sep. Cureus. 2023. PMID: 37868495 Free PMC article.
-
Image-Guided Precision Medicine in the Diagnosis and Treatment of Pheochromocytomas and Paragangliomas.Cancers (Basel). 2023 Sep 21;15(18):4666. doi: 10.3390/cancers15184666. Cancers (Basel). 2023. PMID: 37760633 Free PMC article. Review.
-
The Pheochromocytoma/Paraganglioma syndrome: an overview on mechanisms, diagnosis and management.Int Braz J Urol. 2023 May-Jun;49(3):307-319. doi: 10.1590/S1677-5538.IBJU.2023.0038. Int Braz J Urol. 2023. PMID: 37115176 Free PMC article. Review.
-
Response to Peptide Receptor Radionuclide Therapy in Pheocromocytomas and Paragangliomas: A Systematic Review and Meta-Analysis.J Clin Med. 2023 Feb 13;12(4):1494. doi: 10.3390/jcm12041494. J Clin Med. 2023. PMID: 36836029 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical